Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,770Revenue (TTM) $M1.3Net Margin (%)-19,049.6Altman Z-Score9.8
Enterprise Value $M2,667EPS (TTM) $-5.4Operating Margin %-18,995.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.3Pre-tax Margin (%)-19,049.6Higher ROA y-yN
Price/Book22.810-y EBITDA Growth Rate %2.4Quick Ratio2.3Cash flow > EarningsY
Price/Sales1,9285-y EBITDA Growth Rate %36.1Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-107.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-161.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M47.9ROIC % (ttm)-786.8Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 57.83243%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 57.83157%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 57.8383%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 57.83128%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 57.8396%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 57.8351%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 57.83101%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 57.83116%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.51)
$ 57.83788%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.96)
$ 57.831066%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 57.83636%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 57.83497%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$5015.66view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$5015.66view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$5015.66view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$3092.77view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.28255.22view
Barry RichardDirector 2016-03-14Buy75,000$15.66269.28view
Price Ben GilDirector 2016-03-14Buy4,500$16.7246.29view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82389.26view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82389.26view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95314.55view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
For Traders, Planning Is More Important Than the Plan Sep 25 2016
2:40 am Sarepta Therapeutics prices 5.02 mln shares of its common stock at $59.75 per share Sep 25 2016
[$$] Sarepta Still Has Upside Sep 24 2016
Sarpeta Approval Challenged by FDA (SRPT) Sep 23 2016
Sarpeta Raises Offering After FDA Approval (SRPT) Sep 23 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Sep 23 2016
Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock Sep 22 2016
Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Sep 22 2016
Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock Sep 22 2016
3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering Sep 22 2016
Sarepta Announces Offering of Common Stock (SRPT) Sep 22 2016
Top trades for the 2nd half: BABA, SRPT & more Sep 22 2016
I Am One of the Underinvested Bulls Right Now Sep 22 2016
FDA Commish Says Sarepta's DMD Study Should Be Retracted Sep 22 2016
How Sarepta Is Cashing In on Its FDA Homerun Sep 22 2016
Rite Aid Corporation, WCI Communities & Other Stocks in Spotlight Following Earnings, M&A News and... Sep 22 2016
Sarepta Wins Favorable USPTO Decisions (SRPT) Sep 21 2016
[$$] Sarepta to Sell Up to $225 Million of Stock Sep 21 2016
'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs Sep 21 2016
Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering Sep 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)